top of page
Search

What Is Semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the hormone GLP-1, which is involved in:

  • Stimulating insulin secretion when glucose is high

  • Reducing how much glucagon (a blood-sugar increasing hormone) is released

  • Slowing gastric emptying (so food stays in the stomach longer)

  • Acting in the brain to promote satiety (feeling full) and reduce appetite.

Because of those multiple effects, its uses extend beyond just managing blood sugar.


Orange pill bottle with red lid, spilled white capsules on light blue background. No visible text. Clean, organized scene.
Orange pill bottle with red lid, spilled white capsules on light blue background. No visible text. Clean, organized scene.

Here are the key “non-diabetes” or additional uses, plus possibilities under investigation:

Approved / Established Uses Besides Type-2 Diabetes

  1. Weight Management / Obesity Treatment

    • Under the brand Wegovy, semaglutide is FDA-approved for chronic weight management in adults with obesity (or overweight with weight-related conditions).

    • It helps people lose weight by reducing appetite, increasing feelings of fullness, and reducing calorie intake over time.

  2. Cardiovascular Risk Reduction

    • In people with obesity or type 2 diabetes with existing cardiovascular disease, semaglutide has been shown to reduce risks of major cardiovascular events (e.g., heart attack, stroke, or death) beyond just using it for glucose control.

  3. Kidney-Related Uses

    • Semaglutide is used to help lower the risk of kidney function decline, kidney failure, or death related to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease. This is part of its FDA-approved uses when branded as Ozempic.

  4. Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Non-Alcoholic Fatty Liver Disease (NAFLD / MASLD)

    • Semaglutide has approvals (or accelerated/conditional use) for treatment of nonalcoholic steatohepatitis (NASH), especially in people with moderate to advanced liver fibrosis (without cirrhosis).

Emerging or Investigational / Off-Label Uses

These are not yet fully approved in all jurisdictions, but there is research underway or early evidence:

  • Prevention of Type-2 DiabetesBecause semaglutide improves weight, lowers insulin resistance, etc., it is being looked at (and in some analyses shown) to reduce the risk that people with overweight/obesity will go on to develop type 2 diabetes.

  • Heart FailureEarly studies suggest that for people with obesity-related or overweight-related heart failure, semaglutide may help with symptoms (e.g. reducing fluid retention, improving stamina) beyond what typical treatment does.

  • Other Conditions Probably Under StudyResearch is exploring whether semaglutide may help with conditions such as:

    • Polycystic Ovary Syndrome (PCOS) (due to benefits in weight, insulin sensitivity)

    • Obesity-related sleep apnea (snoring, breathing issues)

    • Liver disease (NAFLD / MASLD beyond just NASH)

    • Potential neurological / neurodegenerative conditions (less mature data)

Things to Keep in Mind (Pros & Limitations)

  • The dose used for weight loss or for treating liver disease (NASH) is higher than typical diabetes doses. So, side effects tend to be more significant if escalated too fast (e.g. GI side effects).

  • These treatments almost always work best in combination with lifestyle modifications: diet, exercise, behavioral support. The medication enhances, does not usually replace, those.

  • Off-label or investigational uses may not be covered by insurance, might carry more legal/regulatory risk or less known long-term safety data.

  • Some benefits (e.g. in cardiovascular risk, kidney protection) are only seen in patients with particular risk profiles (existing cardiovascular disease, etc.). They are not equally applicable to everyone.

How Favor Mental Health Can Use This Information

For your clinic in Bel Air, MD, this topic is particularly useful for content marketing, patient education, and differentiating your services. You can:

  • Educate prospective patients that semaglutide isn’t just for “diabetes” — it may help with weight loss, heart health, liver health, etc.

  • Offer consultations to assess if their health profile meets criteria for non-diabetes indications (e.g. obesity with cardiovascular risk factors, fatty liver disease)

  • Ensure mental health support because changes in weight, appetite, and body image often impact mood, self-esteem, anxiety, etc.

  • Emphasize safety: how you titrate dose, monitor for side effects, integrate lifestyle and mental health support


 
 
 
bottom of page